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Abstract
 
We have characterized the progressive stages of chronic in-
testinal inflammation that develops spontaneously in spe-
cific pathogen-free (SPF) mice with a targeted disruption in
the IL-10 gene (IL-10
 
2
 
/
 
2
 
). Our longitudinal studies showed
that inflammatory changes first appear in the cecum, as-
cending and transverse colon of 3-wk-old mutants. As the
disease progressed, lesions appeared in the remainder of the
colon and in the rectum. Some aged IL-10
 
2
 
/
 
2
 
 mice also de-
veloped inflammation in the small intestine. Prolonged dis-
ease with transmural lesions and a high incidence of col-
orectal adenocarcinomas (60%) was observed in 6-mo-old
mutants. Mechanistic studies have associated uncontrolled
cytokine production by activated macrophages and CD4
 
1
 
Th1-like T cells with the enterocolitis exhibited by IL-10
 
2
 
/
 
2
 
mice. A major role for a pathogenic Th1 response was fur-
ther suggested by showing that anti-IFN
 
g
 
 antibody (Ab)
treatment significantly attenuated intestinal inflammation
in young IL-10
 
2
 
/
 
2
 
 mice. When weanlings were treated with
IL-10, they failed to develop any signs of intestinal inflam-
mation. Interestingly, IL-10 treatment of adults was not
curative but did ameliorate disease progression. Our studies
have also shown that inheritable factors strongly influence
the disease susceptibility of IL-10
 
2
 
/
 
2
 
 mice. In 3-mo-old mu-
tants, intestinal lesions were most severe in IL-10
 
2
 
/
 
2
 
 129/
SvEv and IL-10
 
2
 
/
 
2
 
 BALB/c strains, of intermediate severity
in the IL-10
 
2
 
/
 
2
 
 129 
 
3 
 
C57BL/6J outbreds, and least severe
in the IL-10
 
2
 
/
 
2
 
 C57BL/6J strain. (
 
J. Clin. Invest.
 
 1996. 98:
1010–1020.) Key words: inflammatory bowel disease, colitis,
IFN
 
g
 
 
 
•
 
 adenocarcinoma 
 
•
 
 IL-10 therapy 
 
•
 
 genetic suscepti-
bility
 
Introduction
 
We have reported that outbred mice with a targeted disruption
in the IL-10 gene (IL-10
 
2
 
/
 
2
 
)
 
1
 
 spontaneously develop a general-
ized enterocolitis under conventional housing conditions (1).
When IL-10
 
2
 
/
 
2
 
 mice were derived and maintained under spe-
cific pathogen-free (SPF) conditions, intestinal inflammation
was less severe and occurred only in the mucosa of the proxi-
mal colon (1). The diminished form of disease observed in SPF
IL-10
 
2
 
/
 
2
 
 mice suggested that an uncontrolled immune re-
sponse to normal gut flora may play a causal role. In vitro stud-
ies have shown that IL-10 can be produced by a variety of cell
types and that it possesses both stimulatory and inhibitory ac-
tivities (reviewed in reference 2). It has been hypothesized (1)
that the intestinal disease in IL-10
 
2
 
/
 
2
 
 mice is due to the ab-
sence of the general suppressive effects of IL-10 on cytokine
production by macrophages (3, 4) and Th1 T cells (5). This hy-
pothesis fits well with studies showing that IL-10
 
2
 
/
 
2
 
 mice are
prone to developing exaggerated (pathogenic) immune re-
sponses when challenged with Th1 T cell–dependent or mac-
rophage-dependent antigens. Hence, they are abnormally sen-
sitivity to LPS (6) and to skin irritants including those that
elicit contact hypersensitivity reactions (7).
Recently, it has been discovered that rodents with different
types of gene-targeted disruptions spontaneously develop coli-
tis. These include transgenic mice lacking the T cell receptor
(TcR) 
 
a
 
 chain, TcR 
 
b
 
 chain, TcR 
 
d
 
 
 
3 b
 
 chains (8), G protein
subunit 
 
a
 
i2
 
 (G
 
a
 
i2
 
) (9), TGF-
 
b
 
 (10), and IL-2 (11). As in the
case of IL-10
 
2
 
/
 
2
 
 mice, disease was ameliorated or absent in
mutants (8, 11) raised under specific pathogen-free or germ-
free conditions, respectively. Colitis can also be induced in Tg
 
e
 
26 mice reconstituted with bone marrow (12) and in 
 
scid
 
 mice
reconstituted with CD4
 
1
 
 CD45RB
 
hi
 
 T cells (13, 14). Collec-
tively, these results demonstrate that any number of alter-
ations affecting immunoreactive cells can disrupt the delicate
balance between a protective and a pathogenic response to or-
dinary intestinal flora. 
Chronic inflammatory bowel diseases (IBD) in humans
comprise complex disorders that have been conveniently di-
vided into two major forms, ulcerative colitis (UC) and
Crohn’s disease (CD) (15, 16). Although the etiology of IBD
in humans remains unknown, most evidence implicates an im-
munopathologic response (17–20), perhaps to intestinal flora
(21). Preliminary studies have indicated that transgenic ro-
dents (1, 8–11) and transplanted immunodeficient mice (12–14)
develop phenotypically distinct diseases that resemble either
UC or CD. Therefore, these animals are considered excellent
models for identifying the complex mechanisms involved in
initiating and perpetuating different types of human IBD.
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1.
 
 Abbreviations used in this paper: 
 
Ab, antibody; CD, Crohn’s dis-
ease; H & E, hematoxylin and eosin; IBD, inflammatory bowel dis-
ease; IEL, intraepithelial lymphocytes; IL-10
 
2
 
/
 
2
 
, homozygous for the
IL-10 gene with a targeted disruption; LPL, lamina propria lympho-
cytes; TcR, T cell receptor; Th1, T helper cell, type 1; UC, ulcerative
colitis; wt, wild type.
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Herein, we have characterized the intestinal disorder
present in IL-10
 
2
 
/
 
2
 
 mice including specific features of progres-
sive disease in aging mice and the influence of genetic back-
grounds on disease severity. The results of immunohistologic
and cytokine analyses have linked enterocolitis in IL-10
 
2
 
/
 
2
 
mice to the uncontrolled production of pro inflammatory me-
diators by macrophages and Th1-like T cells. The possibility of
preventing or ameliorating disease by treating IL-10
 
2
 
/
 
2
 
 mice
with anti-IFN
 
g
 
 Ab or IL-10 was also investigated.
 
Methods
 
Animals. 
 
IL-10
 
2
 
/
 
2
 
 mice generated on a C57BL/6/129-Ola background
(1) and wild-type (wt) littermate controls were derived by cesarean
section under specific-pathogen free conditions at Simonsen Labora-
tory (Gilroy, CA) and maintained in micro isolator cages in the ani-
mal care facility at DNAX (Palo Alto, CA). IL-10
 
2
 
/
 
2
 
, wt, and sentinel
mice were periodically examined by the Research Animal Diagnostic
and Investigative Laboratory (University of Missouri, Columbia,
MO). Bacterial cultures, parasitological examinations, serologic tests
and special histological stains were negative for known murine viral
and bacterial pathogens. Therefore, the IL-10
 
2
 
/
 
2
 
 and wt mice used in
our studies are considered to be reared under “clean” rather than
“conventional” conditions.
Unless otherwise specified, all studies were performed with
“clean” chimeric IL-10
 
2
 
/
 
2
 
 mice (C57BL/B6 
 
3 
 
1290la) (1). Other ex-
periments were conducted with “clean” IL-10
 
2
 
/
 
2
 
 mice where the mu-
tated IL-10 gene was selectively bred onto C57BL/6J, BALB/c or 129/
SvEv backgrounds. Normal C57BL/6J, and BALB/c were obtained
from Jackson Laboratories (Bar Harbor, ME) and 129/SvEv mice
were obtained from Taconic (Germantown, NY).
 
Reagents.
 
LPS from 
 
Escherichia coli 
 
(serotype 0111:B4) was ob-
tained from DIFCO (Detroit, MI) and resuspended in pyrogen-free
saline. Recombinant murine IL-10 was expressed in 
 
E. coli 
 
as inclu-
sion bodies and purified after renaturation to homogeneity using hy-
drophobic and ion exchange chromatography. The protein concentra-
tion in the purified preparations was determined by the extinction
coefficient of the protein (1 mg/ml 
 
5
 
 0.36 A280). This material con-
tained 
 
, 
 
0.10 endotoxin units (EU) per mg of protein, and remained
stable at 4
 
8
 
C for at least 6 mo. The specific activity of murine IL-10
(
 
z 
 
1.0 
 
3 
 
10
 
7
 
 U/mg) was determined in a proliferation assay using Ba/
F3 cells expressing the IL-10 receptor (22).
 
Histologic analysis. 
 
Tissues from wt and IL-10
 
2
 
/
 
2
 
 mice were
fixed in 10% neutral buffered formalin, routinely processed, sec-
tioned at 6 
 
m
 
m, and stained with hematoxylin and eosin (H & E) for
light microscopic examination. Samples from lung, heart, liver, kid-
ney, spleen, mesenteric lymph nodes, and the entire gastrointestinal
tract were examined by the same pathologist. Because intestinal le-
sions were multifocal and of variable severity, the grades given to any
section of intestine took into account the number of lesions as well as
their severity. A score from 0 to 4 was based on the following criteria:
(grade 0) no change from normal tissue; (grade 1) one or a few multi-
focal mononuclear cell infiltrates in the lamina propria accompanied
by minimal epithelial hyperplasia and slight to no depletion of mucus
from goblet cells; (grade 2) lesions tended to involve more of the in-
testine than grade 1 lesions, or were more frequent. Typical changes
included several multifocal, mild inflammatory cell infiltrates in the
lamina propria composed primarily of mononuclear cells with a few
neutrophils. Mild epithelial hyperplasia and mucin depletion were
also seen. Small epithelial erosions were occasionally present and in-
flammation rarely involved the submucosa; (grade 3) lesions involved
a large area of the mucosa or were more frequent than grade 2 le-
sions. Inflammation was moderate and often involved the submucosa
but was rarely transmural. Inflammatory cells were a mixture of
mononuclear cells as well as neutrophils, and crypt abscesses were
sometimes observed. Moderate epithelial hyperplasia and mucin de-
pletion were seen. Ulcers were occasionally observed; (grade 4) le-
sions usually involved most of the intestinal section and were more
severe than grade 3 lesions. Inflammation was severe, including
mononuclear cells and neutrophils, and was sometimes transmural.
Epithelial hyperplasia was marked with crowding of epithelial cells in
elongated glands. Few mucin-containing cells were seen. Crypt ab-
scesses and ulcers were present. 
Each segment of the colon (cecum, ascending, transverse, and de-
scending colon and rectum) was given a score based on the criteria
described above and the summation of these scores provided a total
colonic disease score per mouse. The disease scores could range from
0 (no change in any segment) to a maximum of 20 (grade 4 lesions in
all five segments). The small intestine was graded in a similar manner.
 
Ab used for flow cytometry and cell sorting. 
 
All Tri-Color
 
™
 
 mAb
were diluted in 1% (vol/vol) FCS in PBS. The reagents used were:
Tri-Color
 
™
 
-conjugated rat anti–mouse CD4 (clone L3/T4; 6 
 
m
 
g/ml;
Caltag, South San Francisco, CA); phycoerythrin-conjugated rat
anti–mouse CD8
 
a
 
 (clone 53-6.7; 4 
 
m
 
g/ml; Pharmingen, San Diego,
CA); biotin-conjugated rat anti-mouse CD8
 
b
 
 (clone 53-5.8; 5 
 
m
 
g/ml;
Pharmingen); FITC-conjugated CD4 (5 
 
m
 
g/ml; Pharmingen); Tri-
Color
 
™
 
-conjugated streptavidin (1:100 dilution; Caltag); phyco-
erythrin-conjugated hamster anti–mouse 
 
ab 
 
TCR (clone H57-597;
1 
 
m
 
g/ml; Pharmingen); FITC-conjugated hamster anti–mouse 
 
gd
 
 TCR
(clone GL3; 5 
 
m
 
g/ml; Pharmingen); FITC-conjugated rat anti–mouse
CD45RB (clone 16A; 5 
 
m
 
g/ml; Pharmingen), CD44 (clone IM7; 1 
 
m
 
g/
ml; Pharmingen), CD69 (clone H1.2F3; 10 
 
m
 
g/ml; Pharmingen), and
CD62L (clone Mel-14; 10 
 
m
 
g/ml; Pharmingen).
 
Ab used for section staining.
 
All mAb were diluted in 1% (vol/
vol) FCS in PBS. The reagents used were: purified rat anti–mouse
CD4 (clone L3/T4; 4 
 
m
 
g/ml; Caltag); purified rat anti–mouse CD8
 
a
 
(clone 53.67; 4 
 
m
 
g/ml; Pharmingen); rat anti–mouse F4/80 tissue cul-
ture supernatant (clone A3-1; 1:50 dilution; BMA, Westbury, NY);
rat anti–mouse MTS6 (anti–I-A, I-E) kindly provided by Dr. R.L.
Boyd (Monash University, Melbourne, Australia); and rabbit anti–
bovine cytokeratin (broad-spectrum anti–sera; 1:100 dilution; Dako-
patts, Santa Barbara, CA). Second stage Ab were goat anti–rat IgG
(
 
g1
 
L)-FITC (8 
 
m
 
g/ml; Caltag) and rhodamine isothiocyanate-conju-
gated goat anti–rabbit IgM and IgG (H
 
1
 
L) (25 
 
m
 
g/ml; Southern Bio-
technology Associates Inc., Birmingham, AL).
 
Preparation of colon intraepithelial and lamina propria lympho-
cytes. 
 
Gut lymphocytes were isolated from IL-10
 
2
 
/
 
2
 
 or wt mice ac-
cording to a modified protocol of Lefrançois (23). Intestinal tissue
was trimmed of fat and connective tissue and Peyer’s patches were re-
moved. The intestinal tissue was washed extensively in PBS, chopped
and then incubated in 2 mM EDTA in PBS for 30 min at 37
 
8
 
C with
stirring to release intraepithelial lymphocytes (IEL). Lamina propria
lymphocytes (LPL) were isolated from the remaining tissue frag-
ments by incubation in 0.2 mg/mL collagenase/dispase (Boehringer
Mannheim, Indianapolis, IN) for 30 min at 37
 
8
 
C with stirring. The
IEL and LPL preparations were then washed and sieved twice through
nylon gauze (pore size 100 
 
m
 
m) and twice through 70-
 
m
 
m Falcon cell
filters (Becton Dickinson, Franklin Lakes, NJ). Lymphocytes were
enriched by centrifugation within 40% (vol/vol) Percoll (Pharmacia
LKB, Uppsala, Sweden) overlaid on 75% Percoll for 20 min at 750 
 
g
 
. 
Before cell sorting, T cells were enriched by depletion of B cells,
neutrophils and macrophages. Cell preparations were incubated with
anti-B220, -8C5 and -Mac 1 Ab and the Ab-reactive cells were re-
moved in a magnetic field using a combination of goat anti–rat IgG
(Fc) and goat anti–rat IgG (H
 
1
 
L) coated magnetic beads (Advanced
Magnetics, Cambridge, MA). The remaining cells were stained with
CD4-FITC and CD8
 
a
 
-PE for 20 min on ice. Flow cytometric analysis
was performed using a FACScan
 
®
 
 (Becton Dickinson, Sunnyvale,
CA) and data were analyzed using the CellQuest program (Becton
Dickinson). Two-color cell sorting was performed on a FACSTAR
Plus (Becton Dickinson). Populations were 
 
. 
 
98% pure upon reanalysis.
 
Immunofluorescent labeling of tissue sections.
 
Gut tissues were
removed, trimmed of excess fat, and washed extensively in PBS. The
tissue was then immersed in Tissue-Tek embedding compound (Miles
Scientific, Elkhart, IN) and snap-frozen in liquid nitrogen. Tissue
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blocks were stored at 
 
2
 
70
 
8
 
C. Sections (4 
 
m
 
m) were cut using a Reichert-
Jung Frigocut cryostat (Cambridge Instruments Inc., Buffalo, NY)
and immediately air-dried onto glass microscope slides. Tissue sec-
tions were simultaneously stained with specific mAb and anti-cyto-
keratin using a two-step protocol. Sections were first rinsed in 1% (vol/
vol) FCS in PBS and then incubated with 30 
 
m
 
l of primary mAb (as
described above) and rabbit anti-cytokeratin in a humidified staining
box for 20 min at room temperature. Sections were submerged in
PBS three times for 5 min each. Sections were then incubated for 20
min in a mixture of FITC-conjugated goat anti–rat IgG (H
 
1
 
L) (8 
 
m
 
g/
ml; Caltag) and rhodamine-conjugated goat anti–rabbit IgM and IgG
(H
 
1
 
L) (25 
 
m
 
g/ml; Southern Biotechnology Associates Inc., Birming-
ham, AL) and washed as above. Sections were then mounted in
Vectashield Mounting Medium (Vector, Burlingame, CA) under
glass coverslips. FITC labeling was detected using a Zeiss Axioskop
fluorescence microscope (Zeiss, Germany) set on narrow band blue
excitation (440–500 nm), while rhodamine labeling was visualized us-
ing narrow band green excitation (510–565 nm). Photomicrographs
were taken using Kodak 1600 ASA professional color print film.
 
Colon organ culture. Colon organ cultures were prepared from
age-matched wt or IL-102/2 mice in the following manner. Colons,
not including the cecum, were dissected from mice and flushed with
cold PBS to remove fecal matter. Each colon was then cut into 2-mm
squares, washed in a large volume of PBS plus 5% FCS and resus-
pended in RPMI-1640 supplemented with 10% FCS, 50 mM 2-ME,
penicillin (100 U/ml) and streptomycin (100 U/ml). Equivalent
amounts of tissue were distributed into tissue culture plates (Falcon
3046; Becton Dickinson Labware, Lincoln Park, NJ) containing 5 ml
of media alone or media supplemented with LPS (10 mg/ml) or Con
A (5 mg/ml). Cultures were incubated at 378C in 5% CO2. Superna-
tants were harvested after 48 h and stored at 2708C until assayed. 
T cell culture. Sorted CD41 LPL were cultured in 200 ml of
RPMI-1640 containing 5% FCS, 2 mM L-glutamine, 0.05 mM 2-mer-
captoethanol and antibiotics in 96-well flat bottomed plates which
had been previously coated with 10 mg/ml hamster anti–mouse CD3
Ab (clone 32C11). Supernatants from duplicate cultures were har-
vested after 72 h and stored at 2708C before analysis of cytokine lev-
els by ELISA.
Determination of cytokine and nitric oxide (NO) levels. TNFa and
IL-1a levels in cell supernatants were measured using ELISA kits pur-
chased from Genzyme (Boston, MA) according to the manufacturer’s
direction. Other cytokine levels were detected by two-site sandwich
ELISA assays using Ab pairs kindly provided by Dr. J. Abrams
(DNAX): for IFNg, R46A2, and AN18 were used; for IL-6, 32C11 and
20F3; for IL-10, SXC-11, and XT3, and for IL-4, 1D11, and 24G2. NO
levels were measured using Griess reagent, as described previously (24).
Peripheral blood analysis. Blood samples from wt and IL-102/2
mice were obtained via the tail vein. White blood cell counts were de-
termined using a Serono 901 automated counter (Serono Diagnostics,
Allentown, PA). Peripheral blood smears were stained with Wrights-
Giemsa (Sigma Chemical Co., St. Louis, MO). A cell differential was
performed to determine the percent of neutrophils and to calculate
the absolute number of neutrophils per ml of blood. Serum amyloid A
(SAA) levels were determined by ELISA using a kit supplied by Bio-
source (Camarillo, CA) according to the manufacturer’s direction.
Treatments with anti-IFNg antibodies or IL-10. Wt and IL-102/2
mice received weekly i.p. injections of 2 mg of purified rat anti–
mouse IFNg mAb (XMG1.2) or isotype-matched anti–b-galactosi-
dase mAb (GL-117) beginning at 3 wk or 3 mo of age. This amount of
anti–IFNg mAb has been shown to neutralize the activities of endog-
enously produced IFNg in an animal model of IBD (13). In other ex-
periments, IL-102/2 mice received daily i.p. injections of IL-10 (2.5,
10, or 50 mg) or saline beginning at 3 wk and 3 mo of age. Mice were
killed after 8 wk of treatment for pathologic evaluation.
Statistical analysis. Significant differences between experimental
groups were evaluated by the nonparametric Mann and Whitney U
test. A P , 0.05 was considered statistically significant.
Results
Characteristics of progressive enterocolitis in aging IL-102/2
mice. A longitudinal study was performed with pathogen-free
outbred IL-102/2 mice (C57BL/6 3 129 Ola) maintained under
clean conditions in order to study the progression of their in-
testinal disease. Pathologic changes were first seen in 3-wk-old
IL-102/2 mice. These changes consisted of small multifocal in-
filtrates in the lamina propria of the cecum, ascending and
transverse colon and minimal or no epithelial hyperplasia (Fig.
1 B). The infiltrates consisted of lymphocytes occasionally ac-
companied by small numbers of neutrophils. For comparison,
a normal colon from a 3-wk-old wt mouse is shown in Fig. 1 A.
The mean colonic disease score calculated for the group of 3
wk IL-102/2 mice is shown in Table I. Note that at the time of
evaluation only 69% of the young mutants were showing signs
of intestinal disease, which was restricted to the colon. The
other 31% of the mutants were judged as being free of disease
based on the normal histological appearance of their intestinal
tract and other organs and based on their normal peripheral
blood values (see below).
Table I. Longitudinal Study in IL-102/2 Mice
Age n
Percent
of mice
affected
Colonic
disease score
per group
(0–20)§
Percent of mice with 
Granulocytes
per ml blood
(3 1023)§
SAA
mg/ml§
Colorectal
adenocarcinoma Duodenitis‡
IL102/2 Mice
3 wk 16 69% 1.560.4* 0 0 3.760.6* 138629*
3 mo 12 100% 6.660.8* 25% 8% 7.461.0* 617646*
. 6 mo 10 100% 10.161.3* 60% 20% 10.261.3* 9596100*
WT Mice
3 wk 10 0 0 0 0 1.660.3 4768
3 mo 8 0 0 0 0 1.960.3 3966
. 6 mo 4 0 0 0 0 1.960.4 51612
Longitudinal study in IL-102/2 mice. The entire gastrointestinal tract from mice of different ages was evaluated histologically. n indicates the number
of mice per group. §Data reported as mean6SEM per group. ‡Duodenitis was mild with a severity score of 1 (see Histologic analysis in results).
*P , 0.05, IL-102/2 mice vs. age-matched wt mice.
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Figure 1. Histopathology of colonic changes in IL-102/2 mice. (A) Proximal colon from 3-wk-old wt mouse (1503). Note the lack of cellular infil-
trate between glands, and the abundance of mucin in goblet cells; (B) Proximal colon from 3-wk-old IL-102/2 mouse (1503). There is an accumula-
tion of inflammatory cells in the lamina propria between galnds and mucin depletion from goblet cells; (C) Multifocal inflammation and transmural 
disease in 3-mo-old IL-102/2 mouse (153). The tissues at the right and left of the photomicrograph are affected (large arrows) while the tissue in the 
center is relatively normal (small arrow); (D) Higher magnification (1003) of C showing transmural inflammation (arrow); (E) Epithelial hyperpla-
sia, inflammation, and crypt abscesses (1403); (F) Inflammatory infiltrate composed of lymphocytes, macrophages, plasma cells, and a few scat-
tered neutrophils (4403). Epithelial cells lining a gland are on the left; (G) Adenocarcinoma in the rectum (503). Note the neoplastic glands in the 
submucosa. Inflammation and epithelial hyperplasia are present in the mucosa; (H) Higher magnification (2003) of an adenocarcinoma from the 
proximal colon. Several irregular glands lined by well differentiated epithelium are deep in the submucosa. The tunica muscularis is at the bottom.
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By 3 mo of age, multifocal lesions (Fig. 1 C) were seen in
the mutants and were often present in all regions of the large
intestine from the cecum through the rectum. Epithelial hyper-
plasia was quite prominent, inflammation was occasionally
transmural (Fig. 1 D) and crypt abscesses were sometimes
present (Fig. 1 E). Inflammatory infiltrates were composed
predominately of lymphocytes, plasma cells, and macrophages
but also contained small-to-moderate numbers of neutrophils
and eosinophils (Fig. 1 F). Often the infiltrates were present in
both the mucosa and the submucosa. In addition, ulcerations
and colorectal adenocarcinoma (Fig. 1, G and H) were ob-
served. The mean colonic disease score of the 3-mo-old IL-
102/2 mice is shown in Table I. At this age, disease was observed
in 100% of the mice and their score was significantly higher (P ,
0.001) than that of 3-wk-old mutants due to the increased inci-
dence and severity of the lesions. In addition, a small percent-
age of the 3-mo-old mutants developed duodenitis (Table I).
6-mo-old IL-102/2 mice usually had colonic disease qualita-
tively similar to but more severe than that seen at 3 mo of age
(P 5 0.04) (Table I). The higher mean disease score observed
in the 6-mo-old mutants was due, in part, to the fact that they
had more ulcerations and transmural lesions than the 3-mo-old
mutants. 6-mo-old IL-102/2 mice also suffered from a higher
incidence of colorectal adenocarcinoma and duodenitis (Table
I). No metastases were seen in the mesenteric lymph nodes,
liver, or lung. It is not known whether metastases occurred
later as a systematic evaluation was not performed for animals
older than 6 mo.
Blood granulocytosis and elevated serum amyloid A (SAA)
values correlate with disease severity. Blood samples were ob-
tained from wt and IL-102/2 mice of different ages. It was found
that the granulocyte and SAA values were elevated in 3-wk-old
IL-102/2 mice as compared with age-matched wt mice (Table I).
Moreover, these two indicators of inflammation continued to
increase in aging mutants and were roughly correlated with the
severity of their enterocolitis as determined by histological
analyses (Table I). Thus, higher granulocyte and SAA values
were detected in 3-mo-old as compared with 3-wk-old IL-102/2
mice (P 5 0.0006; P 5 0.003) and in 6-mo-old as compared with
3-mo-old IL-102/2 mice (P 5 0.03; P 5 0.009).
Phenotypic analysis of colonic mononuclear cells. Immu-
nohistologic studies of IL-102/2 mice confirmed that patho-
logic changes had occurred as early as 3 wk of age. We found
that small groups of epithelial cells in the colon aberrantly ex-
pressed MHC class II antigen (Fig. 2, A and B) and that there
were slightly increased numbers of CD41 and CD81 T cells in
the lamina propria and minimal to no mucosal hyperplasia (not
shown). In contrast, large numbers of epithelial cells through-
out the colons of older IL-102/2 mice (3-6 mo) expressed MHC
class II antigen. Even though there was widespread expression
of class II antigen by epithelial cells in these older IL-102/2
mice (1), mucosal hyperplasia and inflammatory cells were
only observed in focal areas. These inflammatory infiltrates
contained abnormally high numbers of F4/801 macrophages
(Fig. 2, C and D), CD41 cells (Fig. 2, E and F) and CD8a1 cells
(Fig. 2, G and H). Elevated numbers of Ig1 B cells were also
noted in the lamina propria of the IL-102/2 mice (not shown).
In another set of experiments, colonic T cells were isolated
from the lamina propria of wt and IL-102/2 mice (3 mo) and
the proportions of cells expressing CD4 and/or CD8a were as-
sessed by flow cytometry. In wt mice, the proportion of CD41
versus CD8a1 cells ranged from 1:2 to 1:3 (Fig. 3 A). The high
proportion of CD8a1 cells detected in the wt mice was unex-
pected and appears to be due to the influence of the 129-Ola
genetic background. We have found that wt mice of the 129
strain consistently show a higher frequency of CD8a1 as com-
pared with CD41 LPL (unpublished observation). In contrast
to wt mice, the proportion of cells expressing CD4 versus
CD8a was consistently reversed in the IL-102/2 mice. This
finding suggested that the absolute number of CD41CD8a2
cells in the mutants was increased (see below). The IL-102/2
mice also showed a striking increase in the proportion of
CD41CD8a1 cells. In addition, we found that the majority of
CD41 lymphocytes from the mutants expressed an activated/
memory phenotype as reflected by low levels of CD45RB (Fig.
3 C) (25) and CD62L (Fig. 3 E) molecules and by high levels of
the memory/activation markers, CD69 (Fig. 3 D) and CD44
(Fig. 3 F).
On average, 1.760.44 (3106) LPL were recovered from the
colons of IL-102/2 mice (n 5 8) as compared with 0.860.3 (3106)
LPL recovered from the colons of wt mice (n 5 6). Calcula-
tions revealed that relative to wt mice, the absolute number of
ab TcR CD41 and CD41CD8a1 cells in IL-102/2 mice were in-
creased 6- and 30-fold, respectively. However, our in situ im-
munofluorescence studies suggested that these populations
were concentrated more than 50- to 200-fold in focal lesions
where they may play a pathogenic role. Based on our calcula-
tions, it was determined that the colons of IL-102/2 and wt
mice contained roughly equivalent numbers of CD42CD8a1
cells. This latter finding indicated that the abnormally high
number of CD8a1 cells detected in tissue sections from IL-
102/2 mice (Fig. 2, G and H) was due to an absolute increase in
CD41CD8a1 rather than CD4-CD8a1 T cells.
Cytokine production by colonic tissue and purified CD41
cells. Tissues from the colons of IL-102/2 mice spontaneously
produced larger amounts of IL-1a, TNF-a, IL-6, NO, and
IFN-g as compared with wt tissues (Fig. 4). Under these condi-
tions, IL-4 was undetectable. As the colons of IL-102/2 mice
were found to spontaneously produce high levels of IFN-g and
to contain increased numbers of CD41 T cells, we focused on
the possibility that an unregulated Th1-type response may
contribute to the inflammatory process in this organ. To evalu-
ate this hypothesis, CD41 cells purified by FACS® from the LP
of IL-102/2 and wt mice were stimulated in culture with anti-
CD3 antibodies. CD41 T cells from IL-102/2 mice consistently
produced large quantities of IFN-g relative to CD41 cells from
wt mice. (Fig. 5 A). In fact, the amount of IFN-g produced by
CD41 T cells from wt mice was consistently below the detec-
tion level of our assay (Fig. 5 A, exp. 1). When CD41 T cells
from wt mice were stimulated in the presence of anti–IL-10
mAb, significant levels of IFN-g were produced albeit lower
than that produced by CD41 T cells from IL-102/2 mice (Fig. 5
A, exp. 2). IFN-g levels remained undetectable in the superna-
tants of CD41 T cells from wt mice stimulated in the presence
of isotype control mAb (data not shown). The results obtained
with wt mice demonstrated that endogenously produced IL-10
was capable of suppressing the in vitro production of IFN-g
and thus, it is likely that endogenous IL-10 production medi-
ates a similar affect in vivo when intestinal T cells encounter
enteric antigens. Our experiments also revealed that CD41 T
cells from both wt and IL-102/2 mice produced only small
amounts of IL-4 (Fig. 5 B). This outcome was consistent with
the hypothesis that pathologic changes in the colon of IL-102/2
mice are due to the unregulated activities of Th1-type cells.
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Figure 2. Immunofluorescent staining of frozen colon tissue from wt and IL-102/2 mice. Rhodamine (red) labeling of cytokeratin defines epithelial 
cells. FITC (green) labeling defines specific cell surface markers: (A) MHC class II staining of lamina propria cells of 3 wk wt colon; (B) MHC class 
II staining of lamina propria cells and epithelial cells in 3 wk IL-102/2 colon including surface and crypt (arrow) epithelium where yellow staining 
indicates co-expression of cytokeratin and MHC class II; (C) F4/801 macrophages in lamina propria of 6 mo wt colon; (D) F4/801 macrophages in 
lamina propria of 6-mo IL-102/2 colon, note hyperplasia of colonic mucosa; (E) CD41 T cells in 6 mo wt colon; (F) CD41 T cells in 6 mo IL-102/2 
colon, note hyperplasia of colonic mucosa; (G) CD8a1 T cells predominate in epithelial compartment (arrow) of wt colon; and H) CD8a1 T cells 
are increased in both the epithelial compartment (arrow) and the lamina propria of IL-102/2 colon. A and B, 2003; C–F, 1203; G and H, 2403. 
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Figure 3. Phenotype of colonic T cells. LPL were isolated from IL-102/2 
and wt mice and examined by flow cytometry as described in Methods. 
Profiles are representative of four independent experiments. (A) CD4 
versus CD8a expression on CD3-gated LPL. The percentage of positive 
cells is indicated within each quadrant. Expression of various cell surface 
markers was determined on CD4-gated LPL: (B) isotype control; (C) 
CD45RB; (D) CD69; (E) CD62L (L-selectin); and (F) CD44 (Pgp-1).
Figure 4. Colonic cultures of IL-102/2 mice produce large amounts of 
inflammatory mediators. Colon explants from wt or IL-102/2 mice 
were cultured in media. Six mice per group were analyzed. Superna-
tants were harvested after 48 h of culture and analyzed for cytokine 
levels by ELISA. Data are representative of two independent experi-
ments. *P , 0.05, IL-102/2 mice vs. wt mice.
Figure 5. Purified CD41 T cells from the colons of IL-102/2 mice pro-
duce IFNg but little-to-no IL-4. CD41 T cells were plated at 3 3 104 
cells/well (Exp. 1) or at 2.5 3 105 cells/well (Exp. 2) in anti-CD3 
mAb-coated plates as described in Methods. After 48 h of culture, su-
pernatants were harvested and analyzed for cytokine levels by 
ELISA. *P , 0.05, IL-102/2 mice vs. wt mice.
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Treatment of IL-102/2 mice with anti-IFNg mAb. To deter-
mine the role of IFNg in the development of enterocolitis in IL-
102/2 mice, neutralizing anti-IFNg or isotype control mAbs
were administered weekly to 3-wk-old IL-102/2 mice. Immuno-
histological studies with frozen colon sections revealed that ab-
errant MHC class II expression on epithelial cells of IL-102/2
mice was not detectable after six weeks of anti-IFNg mAb treat-
ment. More importantly, 3-wk-old mutants treated for 6 wk with
anti-IFNg mAb, but not control mAb, showed a diminished in-
cidence of disease (from 93 to 31%) and a reduced mean colonic
disease score (Table II). The anti-IFNg treatment also appeared
to diminish signs of systemic inflammation as evidenced by their
lower blood granulocyte and SAA values when compared with
those of mutants treated with control Ab (Table II).
In contrast, when adult IL-102/2 mice (3 mo old) were
treated with anti-IFNg mAb, the progression of their disease
was unaffected (Table II). Nevertheless, MHC class II expres-
sion by epithelial cells was abolished. These results suggest
that neither IFNg nor MHC class II expression are required
for sustaining disease once it has become established.
Treatment of IL-102/2 mice with IL-10. Intraperitoneal in-
jections of IL-10 (10 mg) were given daily for 8 wk to IL-102/2
weanlings (3 wk) and to diseased adults (3 mo). IL-10 treat-
ment of weanlings completely prevented the development of
enterocolitis (Table III), whereas PBS-treated littermates had
lesions typical of mutants approaching the age of 3 mo (refer
to Table I). After treating diseased adults with IL-10 for 8 wk,
we found that they still had enterocolitis (Table III). Although
the IL-10-treated adults had a lower mean disease score than
that of the PBS-treated controls, the difference was not statis-
tically significant (Table I). Nevertheless, IL-10-treated mice
showed no evidence of duodenitis and a reduced incidence of
colorectal carcinomas. These results suggested that IL-10
treatment diminished disease progression. In a separate exper-
Table II. Neutralization of IFNg in Young IL-102/2 Mice Prevents Colitis
Evaluation of IL-102/2 mice after 6 wk of treatment
Age
treatment
initiated n
Percent
of mice
affected
Colonic
disease score
per group
(0–20)§
Percent of mice with
Granulocytes
per ml blood§
(3 1023)§
SAA
mg/ml§
Colorectal
adenocarcinoma Duodenitis‡
3 wk
16 31% 1.160.4* 0 0 2.160.4* 146631*(anti-IFNg mAb)
3 wk
14 93% 2.760.5 0 0 4.660.5 273635(control mAb)
3 mo
7 100% 9.560.6 28% 57% 9.361.2 7616155(anti-IFNg mAb)
3 mo
12 100% 9.061.8 25% 33% 8.661.2 8016133(control mAb)
Neutralization of IFNg prevents colitis in young IL-102/2 mice. IL-102/2 mice were treated weekly with 2 mg of anti-IFNg mAb. Control mice received
weekly treatments with isotype control mAb. After 6 wk of treatment, their intestinal disease was evaluated histologically.  n indicates the number of
animals per group. §Data reported as mean6SEM per group. ‡Duodenitis was mild with a severity score of 1 (see Histologic analysis in Results).
*P , 0.05, IL-102/2 mice treated with anti-IFNg mAb vs. control mAb.
Table III. Effects of IL-10 Treatment on Enterocolitis in IL-102/2 Mice
Evaluation of IL-102/2 mice after 8 wk of therapy
Age
treatment
initiated n
Percent
of mice
affected
Colonic
disease score
per group
(0–20)§
Percent of mice with
Granulocytes
per ml blood
(3 1023)§
SAA
mg/ml§
Colorectal
adenocarcinoma Duodenitis
3 wk
6 17% 0.260.2* 0 0 1.760.2* 93624*(IL-10)
3 wk
5 100% 6.861.4 0 0 7.261.4 4976126(PBS)
3 mo
7 100% 5.361.3 28% 0 6.861.0 7456144(IL-10)
3 mo
6 100% 10.061.9 67% 33% 9.161.4 1,0256180(PBS)
Effects of IL-10 treatment on enterocolitis in IL-102/2 mice. IL-102/2 mice were given daily i.p. injections of IL-10 (10 mg) or PBS. After 8 wk of treat-
ment, their intestinal disease was evaluated histologically. n indicates the number of animals per group. §Data reported as mean6SEM per group.
‡Duodenitis was mild with a severity score of 1 (see Histologic Analysis in Results). *P , 0.05, IL-102/2mice treated with IL-10 vs. PBS.
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iment, 2.5 or 50 mg of IL-10 were administered daily to dis-
eased adults. The lower dose had marginal or no effect (data
not shown). Treatment with the highest dose was discontinued
because it produced adverse side affects (i.e., malaise and loss
of appetite).
Genetic background influences the severity of enterocolitis
in IL-102/2 mice. The contribution of heritable factors to the
development of intestinal inflammation was evaluated by
backcrossing the IL-10 gene mutation onto C57BL/6J, 129/
SvEv and BALB/c genetic backgrounds. The resulting inbred
strains were evaluated at 3 mo of age, a time when 100% of the
IL-102/2 outbred mice (C57BL/6 3 129/Ola) developed intesti-
nal inflammation. Comparisons of 3-mo-old IL-102/2 C57BL/6
mice with other IL-102/2 strains (Table IV) and outbred mice
(Table I) indicated that the C57BL/6 mutants were relatively
resistant to colitis. In contrast, the disease in 3-mo-old IL-102/2
129/SvEv mice was exacerbated as compared with age-
matched IL-102/2 outbred mice (Table I). In fact, their disease
resembled that displayed by 6-mo-old IL-102/2 outbred mice
except for the absence of duodenitis (Table I). Interestingly,
the IL-102/2 BALB/c strain had a high incidence of lesions
similar to the IL-102/2 129/SvEv mice although they had fewer
carcinomas (Table IV).
Discussion
We have characterized the natural progression of enterocolitis
in pathogen-free IL-102/2 mice and evaluated the genetic and
immunologic components which may be responsible for the
disease process. With respect to disease progression, our stud-
ies have determined that inflammatory lesions in young IL-
102/2 mice begin as small focal areas of inflammation and min-
imal epithelial hyperplasia in the cecum, ascending colon, and
transverse colon. These early lesions contained increased num-
bers of T cells and epithelial cells aberrantly expressing MHC
class II molecules. Interestingly, pathologic changes first ob-
served in 3-wk weanlings occurred at an age when significant
colonization of the gastrointestinal tract with normal flora
takes place (26). Furthermore, the regions where the lesions
were present in young IL-102/2 mice are known to be colo-
nized with the greatest number and types of bacteria (26). A
more severe form of disease was observed in 3-mo-old adults
in which multifocal lesions were present in multiple segments
of the colon and occasionally in the duodenum. Ultimately,
progressive disease in aging IL-102/2 mice was characterized
by an increased number of focal ulcerations and transmural le-
sions. Although these features are reminiscent of those mani-
fested by human patients with Crohn’s disease (15, 16), IL-
102/2 mice also exhibited features atypical of Crohn’s disease.
These include marked crypt hyperplasia, the rare occurrence
of granulomas, fibrosis and lymphoid aggregates, and the ab-
sence of fissures, fistulae, and ileal inflammation. Therefore,
IL-102/2 mice cannot be viewed as a true model of Crohn’s dis-
ease.
A significant finding in 6-mo-old IL-102/2 mice was epithe-
lial hyperplasia. It was not clear whether the hyperplasia de-
veloped at the same time as the inflammation. In some cases
intestinal glands, lined by hyperplastic cells and sometimes
filled with mucus, extended into the underlying submucosa
and occasionally to the serosa. These changes were considered
to represent a non-neoplastic finding consistent with colitis
cystica profunda (27–30). Other lesions were characterized by
more irregular glands, back-to-back growth of glands, small
nests of epithelial cells in the intestinal wall, fibrosis, and slight
loss of nuclear polarity. These lesions were considered to rep-
resent adenocarcinomas similar to those described in Gai2-defi-
cient mice (9). It is recognized that the only unequivocal crite-
rion for malignancy is metastasis (31), and none was observed
in the IL-102/2 mice or in the Gai2 mice. A high incidence of
adenocarcinoma has been observed in the colons of human pa-
tients suffering from prolonged IBD (15, 16, 32, 33). It is not
clear whether these rodent models will be useful in studying
the mechanism(s) responsible for intestinal carcinomas associ-
ated with human IBD.
Ethnic and familial studies in humans have suggested that
certain individuals are genetically predisposed to develop IBD
(34, 35). However, these types of studies have faltered because
they failed to demonstrate a simple type of inheritance due to
a dominant or recessive gene. New rodent models of spontane-
ous intestinal disease offer exciting opportunities to define
modifier genes that determine increased disease susceptibility
or resistance. Our studies have shown that enterocolitis oc-
curred earlier and was more severe in IL-102/2 mice with the
129/SvEv background as compared with the original IL-102/2
outbreds (129/Ola 3 C57BL/6). The IL-102/2 C57BL/6 strain
was least affected. Similarly, colitis in TcR a chain-deficient
mice (TcR a2/2) was more severe in the 129 Sv strain than in
outbred mice (129/Sv 3 C57BL/6) (8). In both models of dis-
Table IV. Effects of Genetic Background on the Development of Enterocolitis in IL-102/2 Mice
Genetic
background n
Percent
of mice affected
Colonic
disease score
per group
(0–20)§
Percent of mice with
Granulocytes
per ml blood
(3 1023)§
SAA
mg/ml§
Colorectal
adenocarcinoma Duodenitis
IL10 2/2 C57BL/6 7 57% 2.961.1* 0% 0 3.460.4* 226666*
IL10 2/2 BALB/c 7 100% 8.661.2* 29% 0 8.061.6* 519662*
IL10 2/2 129 SvEv 9 100% 11.261.4* 67% 0 9.862.1* 1,1326263*
C57BL/6 4 0 0 0 0 1.160.1 54612
BALB/c 4 0 0 0 0 2.160.1 37610
129 SvEv 4 0 0 0 0 2.160.3 2163
Effects of genetic background on the development of enterocolitis in IL-102/2 mice. IL-102/2 mice backcrossed onto C57B1/6J, 129/SvEv, and BALB/c
backgrounds were evaluated for enterocolitis at 3 mo of age. n indicates the number of animals per group. §Data reported as mean6SEM per group.
‡Duodenitis was mild with a severity score of 1 (see Histologic Analysis in results). *P , 0.05, IL-102/2 mice vs age-matched wt mice.
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ease, it appears that the 129 genetic background conferred dis-
ease susceptibility while the C57BL/6 genetic background con-
ferred resistance. Interestingly, TcR a2/2 129/Sv 3 BALB/c
(F2) mice also developed a diminished form of colitis as com-
pared with TcR a2/2 129/Sv mice (8). This finding suggested
that BALB/c, like C57BL/6, is a non-permissive background
for TcR a-deficient mice. Unfortunately, identical backcrosses
have not been made with IL-102/2 mice so direct comparisons
are not possible. Nevertheless, our studies have shown that
BALB/c, in contrast to C57BL/6, is a permissive background
for the development of enterocolitis in IL-102/2 mice. A tenta-
tive conclusion is that different but overlapping subsets of ge-
netic loci govern the distinct forms of enterocolitis observed in
TcR a2/2 and IL-102/2 mice. Hopefully, genetic mapping stud-
ies with these and other rodent models of intestinal disease
(36) will identify the common and unique regulatory genes
that determine disease susceptibility and will ultimately permit
the identification of corresponding genes involved in the heter-
ogeneous forms of human IBD.
A major aim of our study was to investigate the mecha-
nism(s) responsible for enterocolitis in IL-102/2 mice. We
found that intestinal tissue from diseased IL-102/2 mice spon-
taneously produced in vitro exaggerated amounts of cytokines
relative to that of wt tissue. The finding that IL-1a, TNF, IL-6,
and NO levels were elevated and that F4/80 staining cells were
present in very high numbers implied uncontrolled cytokine
production by macrophages contributed to the pathogenic re-
sponse. Abnormally high numbers of abTcR1 CD41 and
CD41CD8a1 T cells were also detected in the colonic lesions.
These CD41 cells were capable of producing large amounts of
IFNg and little-to-no IL-4, typical of Th1 T cells (37). The pos-
sibility that the unregulated activities of macrophages and Th1
cells play a causal role in the disease was not unexpected as in
vitro studies have shown that IL-10 is a potent inhibitor of cy-
tokine production by these cell types (2–5). Theoretically,
IFNg could mediate many deleterious effects such as altering
gut physiology and decreasing epithelial barrier function (38–
40). In addition, the ability of IFNg to heighten cytokine pro-
duction by macrophages (41) exposed to luminal bacterial
products would further amplify the inflammatory response
(40), particularly in the absence of negative regulation by IL-10.
A pathogenic role for IFNg-producing cells in the develop-
ment of enterocolitis by IL-102/2 mice was confirmed by infu-
sion studies with neutralizing anti-IFNg mAb. When IL-102/2
weanlings were treated with anti-IFNg mAb for 6 wk, a
smaller proportion (31%) developed colitis as compared with
weanlings treated with control mAb (93%). Although anti-
IFNg treatment had a beneficial effect, it did not prevent dis-
ease in 100% of the recipients. Therefore, it is likely that the
actions of other inflammatory mediators such as TNF, IL-1,
IL-6, and/or NO also contribute to the induction of disease in
IL-102/2 mutants. These pro-inflammatory mediators have
been linked to IBD in humans (42–45) and to colitis in several
animal models (13, 46). In contrast to the results obtained with
IL-102/2 weanlings, established colitis in adult mutants was un-
altered by 6 wk of treatment with anti-IFNg mAb. However, it
was demonstrated that aberrant Class II antigen expression
was eliminated on the colonic epithelial cells of the treated
adults. Although incomplete neutralization of IFNg could ac-
count for the failure of the treatment to reverse established
disease, it is also likely that while IFNg may be instrumental in
initiating a pathogenic response, it is not required for its con-
tinuation. Additional immune defects, aside from unregulated
IFNg production, must develop in IL-102/2 mice and help per-
petuate intestinal inflammation.
Finally, our studies have shown that two months of IL-10
therapy was very effective in modulating intestinal disease in
young IL-102/2 mice. Mutants treated daily with IL-10 from 3
wk of age remained free of disease. The absence of any patho-
logic changes suggested that IL-10 suppressed the generation
and activities of Th1-like T cells and other immunopathogenic
cells such as macrophages. Recently, it was reported that IL-10
administration prevented the induction of colitis in 63% of scid
mice transplanted with CD45RBhi CD41 T cells whereas, colitis
occurred in 100% of transplant recipients treated with PBS (13).
Striking similarities between this model of colitis and IL-102/2
mice include a pathogenic role for IFNg and the presence of pre-
dominantly mononuclear infiltrates with transmural lesions.
Presently, it is not known if IL-10 can prevent colitis in other an-
imal models of enterocolitis (8–11) where pathogenic mecha-
nisms appear to differ from those identified for transplanted
scid mice (13) and IL-102/2 mice.
Infusion of adult IL-102/2 mice with IL-10 for 2 mo did not
cure their colitis. Because IL-10 therapy did not reverse estab-
lished disease in adults but prevented the development of coli-
tis in weanlings, it is likely that IL-10 plays a key role early in
the immune response by inhibiting the generation of patho-
genic effector cells. Despite the failure of IL-10 therapy to cure
established disease, it reduced the incidence of adenocarcino-
mas and duodenitis associated with progressive disease. One
way in which IL-10 therapy may impede pathological changes
once effector cells have been generated is by simply control-
ling their production of inflammatory mediators. Relevant to
this point, it has been reported that IL-10 enemas adminis-
tered to IBD patients for 10 d resulted in diminished cytokine
production and improved histological scores (47). Future stud-
ies with IL-102/2 mice and other animal models of intestinal
disease will undoubtedly lead to a clearer understanding of the
entire pathogenic process and improve chances of developing
effective treatments for human IBD.
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